血液学领域的共同研究及授权契约:2016年～2025年

血液学合作与许可协议为全面了解世界领先生物製药公司正在进行的血液学交易提供了前所未有的途径。

本报告提供了 2016 年至 2025 年 192 项血液学相关交易的详细资讯。

此报告提供双方宣布的交易付款条款。这些数据为付款条款和其他贸易条款提供了有用的见解。

了解潜在合作伙伴谈判交易条款的弹性可以为谈判过程提供重要的见解，让您了解谈判条款时会发生什么。许多小型企业都希望有详细的付款条款，但当涉及如何付款以及如何转让权利时，细节决定成败。

本报告提供了当前协议交易和合作资料库中记录的自 2016 年以来宣布的合作和许可协议的综合列表，以及可用的财务条款，以及公司及其合作伙伴向美国证券交易委员会提交的实际许可协议文件的在线副本链接。

报告的第一部分描述了血液学贸易和商业活动。第 1 章对报告进行了介绍，第 2 章分析了血液学领域的贸易趋势。

第 3 章介绍了血液学领域已完成交易的财务条款以及发展阶段。交易按标题金额、预付款、里程碑和特许费率列出并分类。

第 4 章回顾了血液学领域交易最活跃的 25 家生物製药公司。对于与美国证券交易委员会 (SEC) 公开宣布的协议交易，可以透过目前协议交易和联盟资料库中的连结在线存取这些协议。

第 5 章全面深入地回顾了自 2016 年以来签署和宣布的血液学交易，并提供合约文件。每个交易标题都透过网路连结连结到实际合约文件的线上版本，从而可以轻鬆、按需存取每个合约文件。

第 6 章提供了按目标列出的血液学交易的综合目录。

该报告还包含大量图表和图形，展示了自 2016 年以来血液学领域的合约趋势和活动。

此外，还提供了按公司 A-Z 和技术类型组织的综合贸易目录。每个交易标题都提供了一个指向在线交易记录的网络链接，并在可用的情况下提供合同文件，从而允许根据需要轻鬆访问每个文件。

主要优点

血液学合作与授权协议为读者提供以下主要优势：

• 了解 2016 年以来的合约趋势
• 查看血液学领域的合作与许可机会
• 基准分析 - 确定交易的市场价值
• 财务条款 – 预付款、里程碑付款、特许权使用费
• 依公司 A-Z、治疗重点、技术类型划分的贸易目录
• 大额交易金额
• 最活跃的交易者
• 确定每笔交易的资产和条款
• 查阅合约文件－洞察交易结构
• 尽职调查 - 评估拟议交易条款对合作伙伴公司的适用性。
• 节省数百小时的研究时间

研究范围

• 《血液学合作与许可协议》旨在更深入地了解世界领先的生物製药公司所达成的交易的动态和结构。

回报内容

• 生物製药产业血液学领域的趋势
• 合作与授权交易结构概述
• 涵盖製药和生物技术的血液学领域交易记录目录
• 主要血液学交易（各价值）
• 最活跃的血液製品许可交易撮合者

目录

摘要整理

第1章 简介

第2章 血液学领域的交易趋势

• 简介
• 多年的血液学领域的联盟
• 各交易类型的血液学领域的联盟
• 各业界的血液学领域的联盟
• 各开发阶段的血液学领域的联盟
• 各技术类型的血液学领域的联盟
• 各治疗适应症的血液学领域的联盟

第3章 血液学领域的联盟的金融交易条件

• 简介
• 公开血液学领域的联盟相关财务条件
• 血液学领域的联盟的主要价值
• 血液学领域的交易的预付款
• 血液学领域的交易的里程金
• 血液学权利金费率

第4章 主要血液学领域的交易和交易厂商

• 简介
• 在血液学领域的联盟最活发生的企业
• 血液学领域的最活跃的交易製造商清单
• 各价值血液学的首位交易

第5章 血液学领域的契约文件名录

• 简介
• 已签约的血液学领域的联盟交易

第6章 按治疗标的血液学领域的交易

• 简介
• 按血液学治疗标的交易
• 交易名录
• 交易目录 - 血液学交易（按公司划分），2016 年至 2025 年
• 交易目录 - 按技术类型划分的血液学交易（2016-2025 年）
• 定义交易类型
• 关于 Biopharma Research Ltd
• 当前合作伙伴关係
• 当前合约
• Current Partnering 的最新报告标题

Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 192 hematology deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of hematology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in hematology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the hematology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in hematology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of hematology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of hematology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in hematology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Hematology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse hematology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Hematology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of hematology trends and structure of deals entered into by leading biopharma companies worldwide.

Hematology Collaboration and Licensing Deals includes:

• Trends in hematology dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of hematology deal records covering pharmaceutical and biotechnology
• The leading hematology deals by value
• Most active hematology licensing dealmakers

In Hematology Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Hematology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in hematology dealmaking

• 2.1. Introduction
• 2.2. Hematology partnering over the years
• 2.3. Hematology partnering by deal type
• 2.4. Hematology partnering by industry sector
• 2.5. Hematology partnering by stage of development
• 2.6. Hematology partnering by technology type
• 2.7. Hematology partnering by therapeutic indication

Chapter 3 - Financial deal terms for hematology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for hematology partnering
• 3.3. Hematology partnering headline values
• 3.4. Hematology deal upfront payments
• 3.5. Hematology deal milestone payments
• 3.6. Hematology royalty rates

Chapter 4 - Leading hematology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in hematology partnering
• 4.3. List of most active dealmakers in hematology
• 4.4. Top hematology deals by value

Chapter 5 - Hematology contract document directory

• 5.1. Introduction
• 5.2. Hematology partnering deals where contract document available

Chapter 6 - Hematology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by hematology therapeutic target
• Deal directory
• Deal directory - Hematology deals by company A-Z 2016 to 2025
• Deal directory - Hematology deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Hematology partnering since 2016
• Figure 2: Hematology partnering by deal type since 2016
• Figure 3: Hematology partnering by industry sector since 2016
• Figure 4: Hematology partnering by stage of development since 2016
• Figure 5: Hematology partnering by technology type since 2016
• Figure 6: Hematology partnering by indication since 2016
• Figure 7: Hematology deals with a headline value
• Figure 8: Hematology deals with upfront payment values
• Figure 9: Hematology deals with milestone payment
• Figure 10: Hematology deals with royalty rates
• Figure 11: Active hematology dealmaking activity since 2016
• Figure 12: Top hematology deals by value since 2016